A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for ...

Biomarker testing has the potential to streamline diagnosis, treatment planning, and anticipation of treatment risks, if done right.

While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

Thermo Fisher Scientific TMO recently announced a collaboration with Pfizer to increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients. The ...

To permanently access this eBook for free, fill out the short form below. Ready to revolutionise your molecular testing for myeloid malignancies? With a constantly expanding list of biomarkers, ...

PHILADELPHIA, March 4, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today ...

Announces majority investment in NGS bioinformatics solution provider Ridom GmbH New NGS microbiology solutions for hygiene testing and epidemiological studies HAI (Hospital-Acquired Infections) ...